The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity ...

This comprehensive review of your health history and goals ensures that your weight loss plan, including any medications, such as Zepbound, is realistic and tailored to your needs. The program ...

Medically reviewed by Kelly Wood, MD Zepbound (tirzepatide) is a once-a-week injectable weight-loss medication. It helps ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare should cover them.